These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 32829006)
1. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer. Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006 [TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157 [TBL] [Abstract][Full Text] [Related]
3. Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells. Li ZF; Yao YD; Zhao YY; Liu Y; Liu ZH; Hu P; Zhu ZR J Clin Lab Anal; 2020 Sep; 34(9):e23362. PubMed ID: 32463132 [TBL] [Abstract][Full Text] [Related]
4. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways. Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. Li Z; Li X; Xu L; Tao Y; Yang C; Chen X; Fang F; Wu Y; Ding X; Zhao H; Li M; Qian G; Xu Y; Ren J; Du W; Wang J; Lu J; Hu S; Pan J Oncol Rep; 2017 Nov; 38(5):2705-2716. PubMed ID: 29048629 [TBL] [Abstract][Full Text] [Related]
6. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492 [TBL] [Abstract][Full Text] [Related]
7. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646 [TBL] [Abstract][Full Text] [Related]
8. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Ahmed T; Shea K; Masters JR; Jones GE; Wells CM Cell Signal; 2008 Jul; 20(7):1320-8. PubMed ID: 18424072 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion. Cai S; Ye Z; Wang X; Pan Y; Weng Y; Lao S; Wei H; Li L J Exp Clin Cancer Res; 2015 May; 34(1):48. PubMed ID: 25975262 [TBL] [Abstract][Full Text] [Related]
10. Recognition of physiological phosphorylation sites by p21-activated kinase 4. Chetty AK; Sexton JA; Ha BH; Turk BE; Boggon TJ J Struct Biol; 2020 Sep; 211(3):107553. PubMed ID: 32585314 [TBL] [Abstract][Full Text] [Related]
11. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Murray BW; Guo C; Piraino J; Westwick JK; Zhang C; Lamerdin J; Dagostino E; Knighton D; Loi CM; Zager M; Kraynov E; Popoff I; Christensen JG; Martinez R; Kephart SE; Marakovits J; Karlicek S; Bergqvist S; Smeal T Proc Natl Acad Sci U S A; 2010 May; 107(20):9446-51. PubMed ID: 20439741 [TBL] [Abstract][Full Text] [Related]
12. DGCR6L, a novel PAK4 interaction protein, regulates PAK4-mediated migration of human gastric cancer cell via LIMK1. Li X; Ke Q; Li Y; Liu F; Zhu G; Li F Int J Biochem Cell Biol; 2010 Jan; 42(1):70-9. PubMed ID: 19778628 [TBL] [Abstract][Full Text] [Related]
13. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417 [TBL] [Abstract][Full Text] [Related]
14. PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Whale AD; Dart A; Holt M; Jones GE; Wells CM Oncogene; 2013 Apr; 32(16):2114-20. PubMed ID: 22689056 [TBL] [Abstract][Full Text] [Related]
15. LIMK1/2 in the mPFC Plays a Role in Chronic Stress-Induced Depressive-Like Effects in Mice. Gao TT; Wang Y; Liu L; Wang JL; Wang YJ; Guan W; Chen TT; Zhao J; Jiang B Int J Neuropsychopharmacol; 2020 Dec; 23(12):821-836. PubMed ID: 32827213 [TBL] [Abstract][Full Text] [Related]
16. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830 [TBL] [Abstract][Full Text] [Related]
18. DADS downregulates the Rac1-ROCK1/PAK1-LIMK1-ADF/cofilin signaling pathway, inhibiting cell migration and invasion. Zhou Y; Su J; Shi L; Liao Q; Su Q Oncol Rep; 2013 Feb; 29(2):605-12. PubMed ID: 23233092 [TBL] [Abstract][Full Text] [Related]
19. Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. Dan C; Kelly A; Bernard O; Minden A J Biol Chem; 2001 Aug; 276(34):32115-21. PubMed ID: 11413130 [TBL] [Abstract][Full Text] [Related]
20. Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K/AKT signaling. He LF; Xu HW; Chen M; Xian ZR; Wen XF; Chen MN; Du CW; Huang WH; Wu JD; Zhang GJ Oncotarget; 2017 Mar; 8(11):17573-17585. PubMed ID: 28407679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]